. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "51781-06-7"@en . . . . "A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent. [PubChem]"@en . "The primary mechanism of the ocular hypotensive action of carteolol in reducing intraocular pressure is most likely a decrease in aqueous humor production. This process is initiated by the non-selective beta1 and beta2 adrenergic receptor blockade."@en . . . . "Humans and other mammals"@en . . . . . "For the treatment of intraocular hypertension and chronic open-angle glaucoma"@en . . "approved"@en . "Carteolol"@en . . . . . . . "Tamura,Y., Nakagawa,K., Yoshizaki,S.and Murakami,N.; U.S.Patent 3,910,924; October 7, 1975; assigned to Otsuka Pharmaceutical Co., Ltd. "@en . . . "# El-Kamel A, Al-Dosari H, Al-Jenoobi F: Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug Deliv. 2006 Jan-Feb;13(1):55-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16401594 # Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A: Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro. Cornea. 2005 Mar;24(2):213-20. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15725891 # Trinquand C, Romanet JP, Nordmann JP, Allaire C: [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study] J Fr Ophtalmol. 2003 Feb;26(2):131-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12660585"@en . "The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension."@en . . "Carteolol"@en . . . " "@en . . . . "Carteololum"@en . . . . . . . . " "@en . . . . .